FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a polypeptide dimer capable of binding to IgE. The polypeptide dimer contains two monomers, each containing the extracellular domain of the alpha subunit of the IgE Fc receptor (FcεRIa-ECD). Also a polynucleotide that encodes a monomer contained in the said polypeptide dimer is proposed, wherein the monomer contains the extracellular domain of the alpha subunit of the IgE Fc receptor (FcεRIa-ECD). Also an expression vector, a host cell, a pharmaceutical composition, a food composition, a method for producing a polypeptide dimer, and a method for treating or preventing an allergic disease are proposed. The polypeptide dimer binds to IgE and exhibits fewer side effects due to the lack of ADCC and CDC functions.
EFFECT: invention can be used to treat or prevent an IgE-mediated allergic disease.
10 cl, 9 dwg, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION CONTAINING PROBIOTICS AND POLYPEPTIDE HAVING BINDING AFFINITY RELATIVELY TO IgE AND ITS USE | 2019 |
|
RU2786578C2 |
| TGF-BETA RECEPTOR ECTODOMAIN FUNCTIONS AND THEIR USE | 2018 |
|
RU2797464C2 |
| ANTI-IGE ANTIBODIES | 2017 |
|
RU2816207C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
| Fc FUSION HIGH AFFINITY IgE RECEPTOR α-CHAIN | 2016 |
|
RU2715606C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| IL4/IL13 RECEPTOR MOLECULE FOR VETERINARY USE | 2018 |
|
RU2795591C2 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
